Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma

Society of Hematologic Oncology Insider news

Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma

Play Episode Pause Episode

1x

00:00 / 00:05:51

Amazon Apple Podcasts Spotify

RSS Feed

Share

Link

Embed

In this SOHO Insider podcast, host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, spoke with Roberto Mina, MD, associate professor of hematology at Emory University, on news from the 2026 ASCO Annual Meeting.

The conversation highlighted a presentation by Dr. Roberto Mina regarding the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies

Follow more news from ASCO here.